These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 30397816)

  • 1. Subjective cognitive decline: preclinical manifestation of Alzheimer's disease.
    Lin Y; Shan PY; Jiang WJ; Sheng C; Ma L
    Neurol Sci; 2019 Jan; 40(1):41-49. PubMed ID: 30397816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
    Rabin LA; Smart CM; Amariglio RE
    Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
    Sannemann L; Bartels C; Brosseron F; Buerger K; Fliessbach K; Freiesleben SD; Frommann I; Glanz W; Heneka MT; Janowitz D; Kilimann I; Kleineidam L; Lammerding D; Laske C; Munk MHJ; Perneczky R; Peters O; Priller J; Rauchmann BS; Rostamzadeh A; Roy-Kluth N; Schild AK; Schneider A; Schneider LS; Spottke A; Spruth EJ; Teipel S; Wagner M; Wiltfang J; Wolfsgruber S; Duezel E; Jessen F;
    J Alzheimers Dis; 2024; 100(1):193-205. PubMed ID: 38848176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging.
    Valech N; Tort-Merino A; Coll-Padrós N; Olives J; León M; Rami L; Molinuevo JL
    J Alzheimers Dis; 2018; 61(2):689-703. PubMed ID: 29254090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internal Consistency Over Time of Subjective Cognitive Decline: Drawing Preclinical Alzheimer's Disease Trajectories.
    Ávila-Villanueva M; Maestú F; Fernández-Blázquez MA
    J Alzheimers Dis; 2018; 66(1):173-183. PubMed ID: 30248053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease.
    Cacciamani F; Tandetnik C; Gagliardi G; Bertin H; Habert MO; Hampel H; Boukadida L; Révillon M; Epelbaum S; Dubois B;
    J Alzheimers Dis; 2017; 59(2):753-762. PubMed ID: 28671134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.
    Moreno-Grau S; Rodríguez-Gómez O; Sanabria Á; Pérez-Cordón A; Sánchez-Ruiz D; Abdelnour C; Valero S; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Lafuente A; Gil S; Santos-Santos MÁ; Alegret M; Espinosa A; Ortega G; Guitart M; Gailhajanet A; de Rojas I; Sotolongo-Grau Ó; Ruiz S; Aguilera N; Papasey J; Martín E; Peleja E; ; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MÁ; Giménez J; Serrano-Ríos M; Orellana A; Tárraga L; Ruiz A; Boada M;
    Alzheimers Dement; 2018 May; 14(5):634-643. PubMed ID: 29156223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Earlier Biomarkers for Alzheimer's Disease: A Multimodal Neuroimaging Study of Individuals with Subjective Cognitive Decline.
    Parker AF; Smart CM; Scarapicchia V; Gawryluk JR;
    J Alzheimers Dis; 2020; 77(3):1067-1076. PubMed ID: 32804127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.
    Buckley RF; Villemagne VL; Masters CL; Ellis KA; Rowe CC; Johnson K; Sperling R; Amariglio R
    J Mol Neurosci; 2016 Nov; 60(3):354-361. PubMed ID: 27514526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of stable and unstable patterns of subjective cognitive decline - results from the Leipzig Longitudinal Study of the Aged (LEILA75+).
    Roehr S; Villringer A; Angermeyer MC; Luck T; Riedel-Heller SG
    BMC Geriatr; 2016 Nov; 16(1):180. PubMed ID: 27814674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
    Wang X; Huang W; Su L; Xing Y; Jessen F; Sun Y; Shu N; Han Y
    Mol Neurodegener; 2020 Sep; 15(1):55. PubMed ID: 32962744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment.
    Thomas KR; Edmonds EC; Eppig J; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2018; 64(1):195-204. PubMed ID: 29865077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The SILCODE Study.
    Sheng C; Lin L; Lin H; Wang X; Han Y; Liu SL
    J Alzheimers Dis; 2021; 82(2):513-526. PubMed ID: 34024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric Cognitive Decline Precedes the Advent of Subjective Cognitive Decline in the Evolution of Alzheimer's Disease.
    Reisberg B; Shao Y; Moosavi M; Kenowsky S; Vedvyas A; Marsh K; Bao J; Buj M; Torossian C; Kluger A; Vedvyas G; Oo T; Malik F; Arain F; Masurkar AV; Wisniewski T
    Dement Geriatr Cogn Disord; 2020; 49(1):16-21. PubMed ID: 32388509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Alzheimer-Associated Neuronal Thread Protein is not Elevated in Patients with Subjective Cognitive Decline and Patients with Depressive State.
    Li Y; Kang M; Wang H; Jin H; Wang X; Gan W; Zhao M; Zhao X; Wang R; Han Y
    J Alzheimers Dis; 2019; 71(4):1115-1123. PubMed ID: 31524164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.